Abstract
We report a case of a 6-week-old infant with diabetes mellitus based on a genetic defect in the sulfonylurea receptor 1 (SUR1), an ATP-sensitive potassium (KATP) channel protein. A spectacular improvement in glucose regulation was shown by real-time continuous glucose monitoring when switching her from insulin to oral glibenclamide. Children with neonatal onset of diabetes deserve genetic testing in order to replace insulin with oral medication.
2014 BMJ Publishing Group Ltd.
MeSH terms
-
Administration, Oral
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / genetics
-
Female
-
Genetic Testing
-
Glyburide / administration & dosage
-
Glyburide / therapeutic use*
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Infant
-
Infant, Newborn
-
Infant, Newborn, Diseases / drug therapy
-
Infant, Newborn, Diseases / genetics
-
Insulin / administration & dosage
-
Insulin / therapeutic use
-
Potassium Channels / genetics*
-
Sulfonylurea Receptors / genetics*
Substances
-
ABCC8 protein, human
-
Blood Glucose
-
Hypoglycemic Agents
-
Insulin
-
Potassium Channels
-
Sulfonylurea Receptors
-
Glyburide